Patent Assignment
Reel/Frame 075478/0138
Security Interest
Recorded: 2026-04-21
Pages: 13
Assignor
OPUS GENETICS, INC.
Executed: 2026-04-02
Assignee
OPCM SA LLC, AS PURCHASER AGENT FOR THE SECURED PARTIES
1700 BROADWAY, 41ST FLOOR C/O OBERLAND CAPITAL MANAGEMENT LLC, NEW YORK, NEW YORK, 10019
Covered Properties
(55)
Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof
Application:
61/759,530 →
Methods and Compositions for Daily Ophthalmic Administration of Phentolamine to Improve Visual Performance
Application:
61/759,542 →
Methods and Compositions for Treatment of Glaucoma and Related Conditions
Application:
62/745,806 →
Methods and Compositions for Treatment of Glaucoma and Related Conditions
Application:
62/752,088 →
Methods and Compositions for Treatment of Presbyopia, Mydriasis, and Other Ocular Disorders
Application:
62/751,391 →
Methods and Compositions for Treating Mydriasis, Glaucoma, and Other Ocular Conditions
Application:
63/178,578 →
Methods and Compositions for Treatment of Diabetic Retinopathy and Related Conditions
Application:
63/182,037 →
Methods and Compositions for Preventing the Progression of Diabetic Retinopathy and Related Conditions
Application:
63/441,054 →
Methods and Compositions for Treatment of Geographic Atrophy
Application:
63/541,631 →
Methods and Compositions for Treating and Preventing the Progression of Intermediate Age-Related Macular Degeneration and Related Conditions
Application:
63/691,862 →
(2E)-2-[(4,5-Dimethoxy-2-Methyl-3,6-Dioxo-1,4-Cyclohexadien-1-Yl)Methylene]-Undecanoic Acid, Salts and Esters Thereof, Polymorphs Thereof, and Therapeutic Uses Thereof
Application:
63/375,647 →
Compositions Comprising an APX3330 Hemicalcium Salt Monohydrate and Therapeutic Uses Thereof
Application:
63/565,345 →
Compositions Comprising an APX3330 Hemicalcium Salt Monohydrate and Therapeutic Uses Thereof
Application:
63/688,036 →
Methods for Synthesizing Phentolamine Mesylate
Application:
63/189,839 →
Gene Therapy for Ocular Disease
Application:
63/437,346 →
Gene Therapy for Ocular Disease
Application:
63/497,850 →
Methods and Compositions for Improving Visual Performance Under Mesopic Light Conditions Using Phentolamine
Application:
63/728,369 →
Methods and Compositions for Improving Visual Performance Under Mesopic Light Conditions Using Phentolamine
Application:
63/761,624 →
Methods and Compositions for Improving Visual Performance Under Mesopic Light Conditions Using Phentolamine
Application:
63/774,557 →
Methods and Compositions for Improving Visual Performance Under Mesopic Light Conditions Using Phentolamine
Application:
63/794,963 →
Methods and Compositions for Improving Visual Performance Under Mesopic Light Conditions Using Phentolamine
Application:
63/812,588 →
Methods and Compositions for Improving Visual Performance Under Mesopic Light Conditions Using Phentolamine
Application:
63/872,617 →
Methods and Compositions for Preventing the Progression of Diabetic Retinopathy and Related Conditions
Application:
19/279,680 →
Publication:
US US20260108483A1
Gene Therapy for Ocular Disease
Application:
19/259,625 →
Publication:
US US20260131026A1
Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof
Application:
19/190,234 →
Publication:
US US20250262149A1
Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof
Application:
19/190,263 →
Publication:
US US20250248931A1
Methods and Compositions for Daily Ophthalmic Administration of Phentolamine to Improve Visual Performance
Application:
18/209,783 →
Publication:
US US20240050412A1
Methods and Compositions for Treatment of Presbyopia, Mydriasis, and Other Ocular Disorders
Application:
17/230,270 →
Publication:
US US20210346349A1
Methods and Compositions for Treating Mydriasis, Glaucoma, and Other Ocular Conditions
Application:
18/556,599 →
Publication:
US US20240216334A1
Methods and Compositions for Treatment of Diabetic Retinopathy and Related Conditions
Application:
18/288,435 →
Publication:
US US20240216315A1
Salts and Esters of APX3330 and Therapeutic Uses Thereof
Application:
18/367,631 →
Publication:
US US20240101505A1
Highly Pure Phentolamine Mesylate and Methods for Making Same
Application:
18/619,535 →
Publication:
US US20240308967A1
Phentolamine Mesylate and Therapeutic Uses Thereof
Application:
18/587,397 →
Publication:
US US20250162995A1
Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof
Application:
19/190,199 →
Publication:
US US20250248930A1
Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof
Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof
Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof
Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof
Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof
Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof
Methods and Compositions for Daily Ophthalmic Administration of Phentolamine to Improve Visual Performance
Methods and Compositions for Daily Ophthalmic Administration of Phentolamine to Improve Visual Performance
Methods and Compositions for Daily Ophthalmic Administration of Phentolamine to Improve Visual Performance
Methods and Compositions for Daily Ophthalmic Administration of Phentolamine to Improve Visual Performance
Methods and Compositions for Treatment of Glaucoma and Related Conditions
Methods and Compositions for Treatment of Presbyopia, Mydriasis, and Other Ocular Disorders
Methods and Compositions for Treatment of Presbyopia, Mydriasis, and Other Ocular Disorders
Methods and Compositions for Treatment of Mydriasis
Methods and Compositions for Treatment of Mydriasis
Methods and Compositions for Treatment of Mydriasis
Methods and Compositions for Treatment of Mydriasis
Salts and Esters of APX3330 and Therapeutic Uses Thereof
Highly Pure Phentolamine Mesylate and Methods for Making Same
Highly Pure Phentolamine Mesylate
Methods and Compositions for Treatment of Presbyopia, Mydriasis, and Other Ocular Disorders
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Sep 18, 2013
From: MEYER, ALAN R.
To: OCULARIS PHARMA, LLC
Reel/Frame 031227/0921 →
Assignment of Assignor's Interest
Sep 18, 2013
From: MEYER, ALAN R.
To: OCULARIS PHARMA, LLC
Reel/Frame 031227/0844 →
Assignment of Assignor's Interest
Jun 17, 2015
From: MEYER, ALAN R.
To: OCULARIS PHARMA, LLC
Reel/Frame 035852/0850 →
Merger
Aug 21, 2018
From: OCULARIS PHARMA, LLC
To: OCUPHIRE PHARMA, INC.
Reel/Frame 046651/0294 →
Merger
Aug 21, 2018
From: OCULARIS PHARMA, LLC
To: OCUPHIRE PHARMA, INC.
Reel/Frame 046651/0342 →
Assignment of Assignor's Interest
Sep 6, 2018
From: MEYER, ALAN R.
To: OCULARIS PHARMA, LLC
Reel/Frame 046806/0305 →
Assignment of Assignor's Interest
Mar 22, 2021
From: PITLICK, WILLIAM H.; MEYER, ALAN R.; SOOCH, MINA; CHARIZANIS, KONSTANTINOS
To: OCUPHIRE PHARMA, INC.
Reel/Frame 055673/0339 →
Assignment of Assignor's Interest
Apr 24, 2021
From: PITLICK, WILLIAM H.; MEYER, ALAN R.; SOOCH, MINA; CHARIZANIS, KONSTANTINOS
To: OCUPHIRE PHARMA, INC.
Reel/Frame 056029/0353 →
Assignment of Assignor's Interest
Apr 29, 2021
From: PEPOSE, JAY STUART; LAZAR, ELIOT STUART; SOOCH, MINA; MEYER, ALAN R.
To: OCUPHIRE PHARMA, INC.
Reel/Frame 056088/0430 →
Assignment of Assignor's Interest
Jun 16, 2021
From: ONICIU, DANIELA CARMEN
To: OCUPHIRE PHARMA, INC.
Reel/Frame 056567/0091 →
Assignment of Assignor's Interest
Dec 15, 2021
From: SOOCH, MINA; CHARIZANIS, KONSTANTINOS; KELLEY, MARK R.; MESSMANN, RICHARD ADAM
To: OCUPHIRE PHARMA, INC.
Reel/Frame 058394/0178 →
Assignment of Assignor's Interest
Sep 21, 2022
From: PITLICK, WILLIAM H.; MEYER, ALAN R.; SOOCH, MINA; CHARIZANIS, KONSTANTINOS
To: OCUPHIRE PHARMA, INC.
Reel/Frame 061166/0374 →
Assignment of Assignor's Interest
Oct 19, 2022
From: ONICIU, DANIELA CARMEN
To: OCUPHIRE PHARMA, INC.
Reel/Frame 061464/0030 →
Change of Address for Assignee
Mar 24, 2023
From: SARA PHARM SOLUTIONS S.R.L.
To: SARA PHARM SOLUTIONS S.R.L.
Reel/Frame 063164/0056 →
Assignment of Assignor's Interest
Mar 24, 2023
From: LUNGAN, MARIA-ANDREEA; PATRASCU, ANDREI-ALUNEL; MANTA, CORINA-MIHAELA
To: SARA PHARM SOLUTIONS S.R.L.
Reel/Frame 063095/0208 →
Assignment of Assignor's Interest
Mar 24, 2023
From: SARA PHARM SOLUTIONS S.R.L.
To: OCUPHIRE PHARMA, INC.
Reel/Frame 063095/0221 →
Assignment of Assignor's Interest
Jul 25, 2023
From: MEYER, ALAN R.
To: OCULARIS PHARMA, LLC
Reel/Frame 064370/0720 →
Merger
Jul 25, 2023
From: OCULARIS PHARMA, LLC
To: OCUPHIRE PHARMA, INC.
Reel/Frame 064370/0706 →
Assignment of Assignor's Interest
Aug 25, 2023
From: CHOUDHARY, MAYUR; JAYAGOPAL, ASHWATH; YERXA, BENJAMIN
To: OPUS GENETICS INC.
Reel/Frame 064708/0384 →
Assignment of Assignor's Interest
Dec 12, 2023
From: CHOUDHARY, MAYUR; JAYAGOPAL, ASHWATH; YERXA, BENJAMIN
To: OPUS GENETICS INC.
Reel/Frame 065841/0566 →
Assignment of Assignor's Interest
Jan 25, 2024
From: SOOCH, MINA; BRIGELL, MITCHELL GEORGE
To: OCUPHIRE PHARMA, INC.
Reel/Frame 066245/0109 →
Assignment of Assignor's Interest
Mar 28, 2024
From: ONICIU, DANIELA CARMEN
To: OCUPHIRE PHARMA, INC.
Reel/Frame 066937/0858 →
Assignment of Assignor's Interest
Jun 7, 2024
From: SARA PHARM SOLUTIONS S.R.L.
To: OCUPHIRE PHARMA, INC.
Reel/Frame 067656/0199 →
Assignment of Assignor's Interest
Jun 7, 2024
From: LUNGAN, MARIA-ANDREEA; PATRASCU, ANDREI-ALUNEL; MANTA, CORINA-MIHAELA
To: SARA PHARM SOLUTIONS S.R.L.
Reel/Frame 067655/0981 →
Assignment of Assignor's Interest
Jun 7, 2024
From: ONICIU, DANIELA CARMEN
To: OCUPHIRE PHARMA, INC.
Reel/Frame 067655/0821 →